ATR Inhibitors and Paclitaxel in Melanoma

A phase I study defined a tolerable combination of the ATR inhibitor ceralasertib with paclitaxel and responses were seen in patients with melanoma who had progressed on an immune check-point inhibitor. This combination warrants further exploration to determine the extent and molecular determinants of clinical activity.

Automated summary

A phase I study found a tolerable combination of the ATR inhibitor ceralasertib with paclitaxel showed responses in melanoma patients who had progressed on an immune check-point inhibitor. Further exploration is needed to determine the extent and molecular determinants of clinical activity.